Insmed Selling And Marketing Expenses from 2010 to 2024

INSM Stock  USD 71.04  1.87  2.56%   
Insmed Selling And Marketing Expenses yearly trend continues to be very stable with very little volatility. Selling And Marketing Expenses is likely to drop to about 12.1 M. During the period from 2010 to 2024, Insmed Selling And Marketing Expenses quarterly data regression pattern had sample variance of 30.3 T and median of  20,802,000. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2010-12-31
Previous Quarter
23.9 M
Current Value
12.1 M
Quarterly Volatility
5.5 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Insmed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Insmed's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.1 M, Interest Expense of 80.1 M or Total Revenue of 320.5 M, as well as many indicators such as Price To Sales Ratio of 13.55, Dividend Yield of 0.0 or Days Sales Outstanding of 46.8. Insmed financial statements analysis is a perfect complement when working with Insmed Valuation or Volatility modules.
  
Check out the analysis of Insmed Correlation against competitors.

Latest Insmed's Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of Insmed Inc over the last few years. It is Insmed's Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Insmed's overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Pretty Stable
   Selling And Marketing Expenses   
       Timeline  

Insmed Selling And Marketing Expenses Regression Statistics

Arithmetic Mean19,129,153
Geometric Mean16,800,190
Coefficient Of Variation28.80
Mean Deviation3,315,641
Median20,802,000
Standard Deviation5,508,951
Sample Variance30.3T
Range22.7M
R-Value0.27
Mean Square Error30.2T
R-Squared0.08
Significance0.32
Slope338,739
Total Sum of Squares424.9T

Insmed Selling And Marketing Expenses History

202412.1 M
202323.9 M
201120.8 M
20101.3 M

About Insmed Financial Statements

Insmed investors utilize fundamental indicators, such as Selling And Marketing Expenses, to predict how Insmed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Selling And Marketing Expenses23.9 M12.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Information and Resources on Investing in Insmed Stock

When determining whether Insmed Inc is a strong investment it is important to analyze Insmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insmed's future performance. For an informed investment choice regarding Insmed Stock, refer to the following important reports:
Check out the analysis of Insmed Correlation against competitors.
You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.27)
Revenue Per Share
2.224
Quarterly Revenue Growth
0.17
Return On Assets
(0.25)
Return On Equity
(14.53)
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.